Anti‐inflammatory drugs as risk modifiers for Alzheimer’s disease: a step towards precision prevention

Abstract

Background: Inflammation is a critical factor in the onset and progression of neurodegenerative diseases, including Alzheimer’s Disease (AD). Notably, inflammatory processes are evident in AD as early as the prodromal stages. Despite this, the role of anti‐inflammatory treatments (aIT) in modifying AD risk remains unclear.

The paper